The Japanese T2D study for evaluating Benefits Of a New first-line therapy with Dapagliflozin in consideration of improving QOL (J-BOND study)
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms J-BOND study
- 03 Mar 2018 Status changed from not yet recruiting to recruiting.
- 21 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 21 Feb 2018.
- 05 Jan 2018 New trial record